Trial Profile
Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALCSG-04
- 02 Aug 2017 New trial record